



Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
SSA-52 (Ro52) (ENA) Antibody, IgG	155 H	AU/mL	[0-40]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
SSA-60 (Ro60) (ENA) Antibody, IgG	101 H	AU/mL	[0-40]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Smith/RNP (ENA) Ab, IgG	5	AU/mL	[0-40]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	3	AU/mL	[0-40]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
PL-12 (alanyl-tRNA synthetase) Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
PL-7 (threonyl-tRNA synthetase) Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
EJ (glycyl-tRNA synthetase) Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
OJ (isoleucyl-tRNA synthetase) Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
SRP (Signal Recognition Particle) Ab	Positive *		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Ku Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
PM/Scl 100 Antibody, IgG	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Fibrillarin (U3 RNP) Ab, IgG	Positive *		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Mi-2 (nuclear helicase protein) Antibody	Negative		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Pl55/140 Antibody	Positive *		[Negative]	19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
TIF-1 gamma (155 kDa) Ab	Positive *			19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
SAE1 (SUMO activating enzyme) Ab	Negative			19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
MDA5 (CADM-140) Ab	Negative			19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
NXP2 (Nuclear matrix protein-2) Ab	Negative			19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02
Myositis Panel Interpretive Data	See Note			19-161-900133	10-Jun-19 12:12:00	10-Jun-19 12:12:00	11-Jun-19 08:13:02

10-Jun-19 12:12:00 SSA-52 (Ro52) (ENA) Antibody, IgG:
 INTERPRETIVE INFORMATION: SSA-52 (Ro52) (ENA) Antibody, IgG

29 AU/mL or Less Negative
 30 - 40 AU/mL Equivocal
 41 AU/mL or Greater Positive

SSA-52 (Ro52) and/or SSA-60 (Ro60) antibodies are associated with a diagnosis of Sjogren syndrome, systemic lupus erythematosus (SLE), and systemic sclerosis. SSA-52 antibody overlaps significantly with the major SSc-related antibodies. SSA-52 (Ro52) antibody occurs frequently in patients with inflammatory myopathies, often in the presence of interstitial lung disease.

10-Jun-19 12:12:00 SSA-60 (Ro60) (ENA) Antibody, IgG:
 REFERENCE INTERVAL: SSA-60 (Ro60) (ENA) Antibody, IgG

29 AU/mL or Less Negative
 30 - 40 AU/mL Equivocal
 41 AU/mL or Greater Positive

10-Jun-19 12:12:00 Smith/RNP (ENA) Ab, IgG:
 INTERPRETIVE INFORMATION: Smith/RNP (ENA) Antibody, IgG

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

Smith/RNP antibodies are frequently seen in patients with mixed connective tissue disease (MCTD) and are also associated with other systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE), systemic sclerosis, and myositis. Antibodies targeting the Smith/RNP antigenic complex also recognize Smith antigens, therefore, the Smith antibody response must be considered when interpreting these results.

10-Jun-19 12:12:00 Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG:
INTERPRETIVE INFORMATION: Jo-1 Antibody, IgG

29 AU/mL or less.....Negative
30-40 AU/mL.....Equivocal
41 AU/mL or greater.....Positive

10-Jun-19 12:12:00 PM/Scl 100 Antibody, IgG:
INTERPRETIVE INFORMATION: PM/Scl-100 Antibody, IgG by
Immunoblot

The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

10-Jun-19 12:12:00 Fibrillarin (U3 RNP) Ab, IgG:
Interpretive Information: Fibrillarin (U3 RNP) Antibody, IgG

The presence of fibrillarin (U3-RNP) IgG antibodies in association with an ANA IFA nucleolar pattern is suggestive of systemic sclerosis (SSc). In SSc, these antibodies are associated with distinct clinical features, such as younger age at disease onset, frequent internal organ involvement (pulmonary hypertension, myositis and renal disease). Fibrillarin antibodies are detected more frequently in African American patients with SSc compared to other ethnic groups. Strong correlation with ANA IFA results is recommended.

In a multi-ethnic cohort of SSc patients (n=98), U3-RNP antibodies detected by immunoblot had an agreement of 98.9 percent with the gold standard immunoprecipitation (IP) assay. Approximately 71 percent (5/7) of the borderline U3-RNP results with ANA nucleolar pattern in this cohort were IP negative.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

10-Jun-19 12:12:00 Myositis Panel Interpretive Data:
INTERPRETIVE INFORMATION: Extended Myositis Panel

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

If present, myositis-specific antibodies (MSA) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAA) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody Specificity	MSA	MAA
SSA 52 (Ro) (ENA) Antibody IgG		X
SSA 60 (Ro) (ENA) Antibody IgG		X
Smith/RNP (ENA) Ab, IgG		X
Jo-1 (histidyl-tRNA synthetase) Ab, IgG	X	
PL-12 (alanyl-tRNA synthetase) Antibody	X	
PL-7 (threonyl-tRNA synthetase) Antibody	X	
EJ (glycyl-tRNA synthetase) Antibody	X	
OJ (isoleucyl-tRNA synthetase) Antibody	X	
SRP (Signal Recognition Particle) Ab	X	
Ku Antibody		X
PM/SCL 100 Antibody, IgG		X
U2 sn (small nuclear) RNP Antibody		X
Fibrillarin (U3 RNP) Ab, IgG		X
Mi-2 (nuclear helicase protein) Antibody	X	
P155/140 Antibody	X	
TIF-1 gamma (155 kDa) Ab	X	
SAE1 (SUMO activating enzyme) Ab	X	
MDA5 (CADM-140) Ab	X	
NXP2 (Nuclear matrix proten-2)Ab	X	

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab